key: cord-0744662-nvl0tu70
authors: Feng, Yi-Fu; Wang, Kun-Peng; Mo, Jing-Gang; Xu, Ying-He; Wang, Lie-Zhi; Jin, Chong; Chen, Xiang; Yi, Bin
title: The spatiotemporal trend of renal involvement in COVID-19: a pooled analysis of 17,134 patients
date: 2021-04-03
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.03.082
sha: fe29b75cb45afda76a9c7fab42bd71c203fd2552
doc_id: 744662
cord_uid: nvl0tu70

Background The spatiotemporal trend of renal involvement in Coronavirus Disease 2019(COVID-19) patients is still unclear. Therefore, we seek to reveal the dynamics of renal involvement superimposed COVID-19 according to time and space. Methods The COVID-19 patients reporting the renal involvement were enrolled in our study. We collected the following information: the first author, patient demographics, patients enrolled period, location, definition of acute kidney injury (AKI), prevalence of AKI and renal replacement treatment (RRT). Results 17,134 patients were included finally. The overall prevalence of AKI in COVID-19 patients was 19%, which 7% of them underwent RRT. And the overall risk of AKI in patients enrolled before March 1, 2020 (9%) was significantly lower than that after March 1, 2020 (36%) (P < 0.00001). Moreover, the overall risk of AKI outside Asia (35%) was significantly higher than that in Asia (10%) (P < 0.00001). Additionally, similar to patients required RRT, AKI patients would more tend to become seriously ill or even die (P < 0.00001). Conclusions This study firstly reports that renal involvement superimposed COVID-19, a comorbidity portending a poor prognosis, has become an increasingly serious problem over time, and more common outside Asia. Thus, more concerns should be offered to manage the specific group of patients.

Coronavirus Disease 2019(COVID-19) is a novel respiratory infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has reopened the issue of the role and importance of coronaviruses in human pathology (World Health Organization, 2020a) . In fact, only seven of coronaviruses are called zoonotic and have the ability to jump from animals to humans. Four of them cause mild illness, such as the common cold, while other three types have triggered more catastrophic repercussions including SARS coronavirus, Middle East respiratory syndrome coronavirus, and now SARS-CoV-2 (Čivljak et al., 2020) .

Taking account of the alarming levels of spread and severity all over the world, COVID-19 has been characterized as a pandemic by the World Health Organization (WHO), and no country could manage alone or stand aloof (World Health Organization, 2020b) . The number of affected countries, cases, and deaths are sharply climbing at an alarming rate. Up to June 30, 2020, more than 210 countries and territories have been affected by the crisis, with a total of 10,185,374 confirmed cases, and 503,962 deaths (World Health Organization, 2020c) . Moreover, COVID-19 has brought a great impact on mental health, education, finance, transportation, economy, and so on (Codagnone et al., 2020; Gautam et al., 2020; McKee et al., 2020; Sharma et al., 2020a; Sharma et al., 2020b) .

Early screening for clinical suspicion could effectively control this spread. In addition to the symptoms in the respiratory system such as fever, fatigue, and unproductive cough, the clinical manifestations in patients with COVID-19 include diarrhea, septic shock, and even multiple organ dysfunction syndromes . Comorbidity superimposed COVID-19 patients is usually an indicator of J o u r n a l P r e -p r o o f more severe disability and lower survival rate. Although a recent study has suggested that renal involvement is uncommon in COVID-19 , it may lead to a poor prognosis, when acute kidney injury(AKI) develops in COVID-19 patients.

More importantly, few studies focus on the spatiotemporal trend of renal involvement superimposed COVID-19. Therefore, we seek to conduct a pooled analysis of available studies for reporting renal involvement in COVID-19 based on the spacetime structure.

This study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (Moher et al., 2009) .

All studies reported renal involvement in COVID-19 patients and published up to June 30, 2020 were identified from the PubMed, Scopus and Web of Science databases. The searching words were "COVID-19", "coronavirus disease 2019", "SARS-CoV-2", "severe acute respiratory syndrome coronavirus 2", "nCoV", "novel coronavirus", "corona virus", "kidney", "renal" and "nephrology". References cited in the retrieved original articles were also reviewed without language limitations. Two investigators (YFF and KPW) independently analyzed these publications by titles and abstracts. Full texts were reviewed for any potentially relevant studies.

Included literatures should meet the following criteria: (I) observational studies;

(II) study sample should be more than 10; (III) study patients should be confirmed to J o u r n a l P r e -p r o o f be infected with SARS-CoV-2; (IV) the prevalence of AKI in COVID-19 patients should be reported.

Besides, the following studies would be excluded: (I) repeatedly published articles; (II) the editorial, commentary, guidance, perspective, reply, review and single case reports; (III) studies containing uncertain data; (IV) studies lacked of available data; and (V) studies on other coronavirus diseases, such as SARS and Middle East respiratory syndrome.

The primary outcome in this study was the prevalence of AKI superimposed COVID-19. And the requirement of renal replacement treatment (RRT) was the secondary outcome.

Two investigators (YFF and KPW) independently conducted data extraction and quality assessment, dissensions were settled by a third investigator (BY). We fetch the following information from each study: first author, patient demographics, patients enrolled period, location, definition of AKI, prevalence of AKI, and requirement of RRT. If necessary, corresponding authors of included studies were contacted directly for additional data. Disease severity and mortality were defined according to the studies, if authors did not report severity classification of COVID-19, we would classify patients who developed acute respiratory distress syndrome, needed mechanical ventilation, or admitted to intensive care units as severe cases. The risk of bias was applied as the quality assessment tool for case series studies published by the National Institutes of Health, which poses nine questions, such as study objective, study population and study intervention (Mao et al., 2020) . (Chen et al., 2014) . Risk ratios (RRs) with 95% CI of the outcome measures were used for the subgroup analyses based on disease severity and mortality. For the robustness of our pooled effects, we conducted our meta-analysis with random-effects models by the inverse variance method. The publication bias was judged by the symmetry of the funnel plot (Mao et al., 2020). We defined significant heterogeneity within and/or between studies when I 2 > 50%, otherwise, the heterogeneity was not substantial. P< 0.05 was considered statistically significant (Yi et al., 2020) .

Initially, 2,751 records were retrieved, including 606 from PubMed, 1,649 from Scopus, and 496 from Web of Science. After removing 809 duplicate records, 1,849 records were also eliminated based on the title and abstract. Finally, a total of 30 eligible studies (Aggarwal et al., 2020; Antinori et al., 2020; Argenziano et al., 2020; Bhargava et al., 2020; Cao et al., 2020a; Chen et al., 2020a; Chen et al., 2020b; Cheng et al., 2020; Cummings et al., 2020; Deng et al., 2020; Hirsch et al., 2020; Hong et al., 2020; Li et al., 2020a; Li et al., 2020b; Li et al., 2020c; Malberti et al., 2020; Pei et al., 2020; Richardson et al., 2020; Shi et al., 2020a; Shi et al., 2020b; J o u r n a l P r e -p r o o f 2020c; Yang et al., 2020a; Yang et al., 2020c; Yang et al., 2020d; Yu et al., 2020; Zhang et al., 2020a; Zhang et al., 2020c; Zhao et al., 2020; Zheng et al., 2020) were identified in this study, according to the full-text evaluation for 93 potentially relevant studies ( Figure 1 ).

Overall, there were 17,134 patients in these 30 studies, among which 13 studies described the prevalence of AKI in patients with severe versus non-severe COVID-19 (Aggarwal et al., 2020; Antinori et al., 2020; Argenziano et al., 2020; Bhargava et al., 2020; Cao et al., 2020a; Chen et al., 2020a; Hirsch et al., 2020; Hong et al., 2020; Pei et al., 2020; Zhang et al., 2020; Zhao et al., 2020; Zheng et al., 2020) , and five studies described the ratio of the probability of AKI in COVID-19 survivals versus non-survivals (Chen et al., 2020b; Deng et al., 2020; Richardson et al., 2020; Wang et al., 2020c; Yang et al., 2020d) . In the majority of studies, AKI was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria (Yi et al., 2017) . Besides, patients were enrolled at different periods in these studies: 20 studies enrolled patients before March 1, 2020 Chen et al., 2020b; Cheng et al., 2020; Deng et al., 2020; Li et al., 2020a; Li et al., 2020b; Li et al., 2020c; Pei et al., 2020; Shi et al., 2020a; Shi et al., 2020b; Wang et al., 2020c; Yang et al., 2020a; Yang et al., 2020c; Yang et al., 2020d; Yu et al., 2020; Zhang et al., 2020a; Zhang et al., 2020c; Zhao et al., 2020) , and six studies enrolled patients after March 1, 2020 (Aggarwal et al., 2020; Argenziano et al., 2020; Bhargava et al., 2020; Cummings et al., 2020; Hirsch et al., 2020; Richardson et al., 2020) .

In addition, the locations differed in 30 studies, including one from South Korea (Hong et al., 2020) , two from Italy (Antinori et al., 2020; Malberti et al., 2020) , six from the United States of America (Aggarwal et al., 2020; Argenziano et al., 2020; Bhargava et al., 2020; Cummings et al., 2020; Hirsch et al., 2020; Richardson et al., 2020) , and others from China Chen et al., 2020a; Chen et al., 2020b; Cheng et al., 2020; Deng et al., 2020; Li et al., 2020a; Li et al., 2020b; Li et al., 2020c; Pei et al., 2020; Shi et al., 2020a; Shi et al., 2020b; Wang et al., 2020c; Yang et al., 2020a; Yang et al., 2020c; Yang et al., 2020d; Yu et al., 2020; Zhang et al., 2020a; Zhang et al., 2020c; Zhao et al., 2020; Zheng et al., 2020) . Quality scores of all studies ranged from 5 to 6, representing a moderate risk of bias (Supplementary Table 1 ). The main characteristics and quality assessments of these studies were summarized in Table 1 .

The prevalence of AKI varied from 0.3% to 68.8% in all 30 studies. AKI occurred in 4,197 COVID-19 patients, with a 19% pooled probability (95% CI 13% -24%, I 2 = 99%) in our analysis (Figure 2 ).

For the high heterogeneity, we explored the possible confounders in these studies. As listed in Table 1 , all 30 studies were conducted at different periods. The subgroup analysis, based on the time point-March 1, 2020, indicated that high heterogeneity existed before and after the time point (X 2 =46.29, df = 1, I 2 =97.8%; Table 2 ). AKI emerged in 329 out of 4,256 patients enrolled before March 1, 2020 among 20 studies Chen et al., 2020a; Chen et al., 2020b; Cheng et al., 2020; Deng et al., 2020; Li et al., 2020a; Li et al., 2020b; Li et al., 2020c; Pei et al., 2020; Shi et al., 2020a; Shi et al., 2020b; Wang et al., 2020c; Yang et al., 2020a;  J o u r n a l P r e -p r o o f Yang et al., 2020c; Yang et al., 2020d; Yu et al., 2020; Zhang et al., 2020c; Zhao et al., 2020) , and 3,824 out of 12,469 patients after March 1, 2020 cross six studies (Aggarwal et al., 2020; Argenziano et al., 2020; Bhargava et al., 2020; Cummings et al., 2020; Hirsch et al., 2020; Richardson et al., 2020) , respectively. Overall, there was a significant difference between the pooled risk of AKI in enrolled patients before (9%; 95% CI, [7%, 12%]) and after that time point (36%; 95% CI, [28%, 43%]) (P < 0.00001).

During the analysis, we observed that the 30 studies were from four counties, including South Korea, Italy, the United States of America, and China. Given that South Korea and China are located in Asia, we conducted the sub-group analysis based on studies in and outside Asia. The test for sub-group differences was listed in 

Compared with those who had non-severe COVID-19, patients with severe COVID-19 showed a significantly higher risk to develop AKI (13 studies; 7,583 participants; RR,3.72; 95% CI, [2.65, 5.32]; P < 0.00001; I 2 =79%; Figure 3A ) (Aggarwal et al., 2020; Antinori et al., 2020; Argenziano et al., 2020; Bhargava et al., 2020; Cao et al., 2020a; Chen et al., 2020a; Hirsch et al., 2020; Hong et al., 2020; Pei et al., 2020; Zhang et al., 2020; Zhao et al., 2020; Zheng et al., 2020) . Moreover, AKI also showed statistical differences between COVID-19 survivals and non-survivals (five studies; 6,358 participants; RR, 10.30; 95% CI, [2.93, 36.22]; P < 0.00001; I 2 =76%; Figure 3B ) (Chen et al., 2020b; Deng et al., 2020; Richardson et al., 2020; Wang et al., 2020c; Yang et al., 2020d) .

A total of 792 in 13,982 COVID-19 patients needed RRT in 15 studies (Argenziano et al., 2020; Cao et al., 2020a; Chen et al., 2020b; Cummings et al., 2020; Hirsch et al., 2020; Hong et al., 2020; Malberti et al., 2020; Richardson et al., 2020; Shi et al., 2020a; Shi et al., 2020b; Yang et al., 2020d; Yu et al., 2020; Zhao et al., 2020; Zheng et al., 2020) , and the pooled requirement of RRT was 7% (95% CI 5% -9%, I 2 = 96%) (Figure 4 ). Non-severe COVID-19 patients showed a significantly lower risk of RRT than that in severe COVID-19 patients (seven studies; 6,845 participants; RR,0.06; 95% CI, [0.02, 0.25]; P < 0.00001; I 2 =89%; Figure 5A ) (Argenziano et al., 2020; Cao et al., 2020a; Hirsch et al., 2020; Hong et al., 2020; Zhang et al., 2020a; Zhao et al., 2020; Zheng et al., 2020) . In addition, RRT occurred less frequently in COVID-19 survivals, compared with nonsurvivals (three studies; 6,026 participants; RR, 0.20; 95% CI, [0.16, 0.26]; P < 0.00001; I 2 =0%; Figure 5B ) (Chen et al., 2020b; Richardson et al., 2020; Yang et al., 2020d) .

Significant publication bias was noticed on the basis of the funnel plot for AKI (Supplementary Figure 1) but not for RRT (Supplementary Figure 2) .

This report firstly provides a comprehensive overview of the available evidence on the spatiotemporal trend of renal involvement in COVID-19. A total of 17,134 patients in 30 studies from four countries were included. The analysis revealed that the overall risk of AKI in COVID-19 patients was 19%, with a significant spatiotemporal difference. Moreover, patients with AKI, similar to patients who needed RRT, would be more likely to get seriously sick or even die.

SARS-CoV-2, following SARS coronavirus and Middle East respiratory syndrome coronavirus, has caused the third coronavirus epidemic in the third millennium (Čivljak et al., 2020) . Coronaviruses, which belong to the family Coronaviridae, are a large group of RNA viruses named after their spiky structure that look a bit like a corona, or crown (González et al., 2003) . Like its relatives, SARS-CoV-2 is spherical with spike proteins, which cause the coronavirus to latch onto cells that it can invade. Once a virus enters the human body through the eyes, mouth, or nose, it looks for cells with its favorite doorways-proteins called receptors. If the virus finds a compatible receptor, it can invade and start replicating itself. For SARS-CoV-2, that receptor is found across the entire body (Hirano and Murakami, 2020) .

The attachment of SARS-CoV-2 spike protein to angiotensin-converting enzyme 2 (ACE2), the cellular receptor, can promote the invasion, replication and J o u r n a l P r e -p r o o f intercellular transmission of the virus (Hirano and Murakami, 2020) . Although there was no evidence of glomerular involvement, immunohistochemistry indicated that SARS-CoV-2 nucleoprotein antigen was overexpressed in the tubular cells, and accompanied by severe acute tubular necrosis (Puelles et al., 2020) . The biomolecular interactions between SARS-CoV-2 and ACE2 expressed in kidneys were considered inevitable companions of the process of AKI in patients infected with this virus. On the other hand, immune-mediated disorders of the kidney could be one possible explanation for AKI in COVID-19. SARS-CoV-2 infection would result in disturbances of T1 and T2 immune responses (Hoiland et al., 2020) , and contribute to the growth in the levels of cytokines and chemokines including interleukin-4, interleukin-6 and interferon-inducible protein-10 (Hirano and Murakami, 2020) . In addition, the toxicity of drugs might lead to AKI in patients suffering from novel coronavirus pneumonia, based on the fact that pharmacotherapy was the key approach to manage it (Peng et al., 2020).

To our surprise, the risk of AKI in COVID-19 confirmed patients did not show a downward trend over time as expected. Instead, the subgroup analysis, according to patients enrolled period, showed that the overall risk of AKI in patients enrolled period after March 1, 2020 (36%) was higher than that before March 1, 2020 (9%).

The mutation of SARS-CoV-2 might play a role in this finding. SARS-CoV-2 is an RNA virus with a high mutation rate, which can contribute to transmission and virulence. A recent study (Hu et al., 2020) , which elaborated the dominant mutation of SARS-CoV-2 at the 614 position of spike protein (D614G mutation), reported that the proportion of D614G strain in all SARS-CoV-2 increased from 0 in early 2020 to 70% in May 2020, which meant the mutant strain had become the dominant strain globally. Moreover, Choe et al. found that the D614G mutation in SARS-CoV-2 J o u r n a l P r e -p r o o f could increase the number of spike protein, and facilitate the viral invasion . During the investigation, we found that patients enrolled period before March 1, 2020 were from Asia. Therefore, the subgroup analysis based on the location was further performed.

Generally, there was less AKI in Asia (10%) compared with that outside Asia (35%). Given that Caucasians are the vast majority of the population in Italy and the United States of America, it may be inextricably bound up with ethnic differences in the frequency of variants on ACE2, the cellular receptor of SARS-CoV-2. ACE2 variants, which are determined by genes, have been known to differ in frequency among populations (Cao et al., 2020b; Strafella et al., 2020) . The virus might attach to receptors with higher affinity, if more ACE2 gene variants are expressed in the epithelial cells of the renal tubule among Caucasians. On the contrary, these ACE2 variants may be less expressed in Asians, who less frequently present AKI in these COVID-19 patients. Moreover, it could be inferred that the sharp cultural differences also play an important role in the different risk between Caucasians and Asians, such as attitudes about wearing a facemask, keeping a safe social distance, and strategies of containment.

The limitations of the present study are as follows. Firstly, as described earlier, the heterogeneity of this study is high among studies and publication bias is noticed for several outcomes. Therefore, cautions should be raised when drawing conclusions, although we have accounted for this heterogeneity by using a random effects model and performing subgroup analysis. Secondly, the definitions of AKI discorded among all included studies, albeit the KDIGO criteria were applied in most studies to define AKI. However, we could not prompt further investigation, due to a lack of information pertaining to AKI definition in some studies. Thirdly, the renal function indexes-including serum creatinine, blood urea nitrogen, endogenous creatinine clearance rate and estimated glomerular filtration rate-have not been evaluated, for the reason that the raw data in 30 studies were too scarce to conduct meta-analyses.

In sum, our study presented the first report to estimate the spatiotemporal trend of renal involvement in COVID-19, which may act as a sign of deterioration. This study revealed that COVID-19 patients enrolled after March 1, 2020, had a higher risk of renal involvement than that before March 1, 2020. Besides, compared with patients outside Asia, patients in Asia had a lower risk of renal involvement. It entails constant vigilance and effort to manage these patients. 

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States

Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status

Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series

Predictors for severe COVID-19 infection

Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

Clinical and immunological features of severe and moderate coronavirus disease 2019

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Implement meta-analysis with non-comparative binary data in RevMan Sofware

Kidney disease is associated with in-hospital death of patients with COVID-19

The third coronavirus epidemic in the third millennium: what's next?

Italy, Spain, and the United Kingdom

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study

2019-nCoV pandemic: a disruptive and stressful atmosphere for Indian academic fraternity

COVID-19: a new virus, but a familiar receptor and cytokine release syndrome

Acute kidney injury in patients hospitalized with COVID-19

Amelioration of COVID-19 related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome

Clinical features and outcomes of 98 patients hospitalized with SARS-CoV-2 infection in Daegu, South Korea: a brief descriptive study

The D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity and decreases neutralization sensitivity to individual convalescent sera

Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study

Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center

Analysis of clinical features and outcomes of 161 patients with severe and critical COVID-19: a multicenter descriptive study

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Analysis of ACE2 genetic variability among populations highlights a possible link with COVID-19-related neurological complications

Gao GF A novel coronavirus outbreak of global health concern

Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan

Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China

COVID-19) and the virus that causes it. World Health Organization: Geneva, Switzerland 2020a. World Health Organization. WHO declares COVID-19 a pandemic

The role of essential organ-based comorbidities in the prognosis of COVID-19 infection patients

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

Remote ischaemic preconditioning reduces acute kidney injury in adult patients undergoing cardiac surgery with cardiopulmonary bypass: a meta-analysis

Nicorandil for periprocedural myocardial injury in elective percutaneous coronary intervention: a meta-analysis of 10 randomized controlled trials

China: a cross-sectional study

Clinical features and shortterm outcomes of 221 patients with COVID-19 in Wuhan

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity

Epidemiological, clinical J o u r n a l P r e -p r o o f characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings

Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study

COVID-19 patients admitted to intensive care unit in Hangzhou

We appreciate the works by the authors of included 30 studies, and all reviewers and editors for reviewing this work.J o u r n a l P r e -p r o o f

Not applicable.

The authors declared no conflict of interests to disclose. Mar Abbreviations: IV = inverse variance method; CI = confidence interval.J o u r n a l P r e -p r o o f